Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Science Center ?? Gainesville
mi
from
Gainesville, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Science Center ?? Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Downey Medical Center
mi
from
Downey, CA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Downey Medical Center
mi
from
Downey, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
AMG 386 and Abiraterone for Advanced Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AMG 386 and Abiraterone for Advanced Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
AMG 386 and Abiraterone for Advanced Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
AMG 386 and Abiraterone for Advanced Prostate Cancer
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Northshore Hospital
mi
from
Evanston, IL
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Northshore Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Healthcare
mi
from
Grand Rapids, MI
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Healthcare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical Center
mi
from
New York, NY
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
St. Mark's Hospital
mi
from
Salt Lake City, UT
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
St. Mark's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Sentra Norfolk General Hospital
mi
from
Norfolk, VA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Sentra Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Wayne State Harper Hospital
mi
from
Detroit, MI
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Wayne State Harper Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance/University of Washington Medical Center
mi
from
Seattle, WA
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance/University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
OLV Hospital Aalst
mi
from
Aalst,
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
OLV Hospital Aalst
mi
from
Aalst,
Click here to add this to my saved trials
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
Sarcoma Alliance for Research Through Collaboration
mi
from
Ann Arbor, MI
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
Sarcoma Alliance for Research Through Collaboration
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute
mi
from
Palo Alto, CA
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials